Ambrx Biopharma (AMAM) News Today → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free AMAM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLatest News for Johnson & Johnson Stock (NYSE:JNJ)benzinga.com - April 5 at 9:05 PMAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & Johnsonfinanznachrichten.de - March 7 at 10:52 AMJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash Dealmarkets.businessinsider.com - March 7 at 10:52 AMAmbrx Shareholders Approve Acquisition by Johnson & Johnsonglobenewswire.com - March 6 at 1:20 PMFmr LLC Sells 449,560 Shares of Ambrx Biopharma Inc. (NYSE:AMAM)marketbeat.com - March 5 at 6:27 AM70,000 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Bought by Monashee Investment Management LLCmarketbeat.com - February 25 at 10:54 AM3 Stocks to Buy That Are Up 200% or More in 2024investorplace.com - February 23 at 2:19 PMIs Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?msn.com - February 20 at 11:36 AMAmbrx Biopharma Inc. (NYSE:AMAM) Receives Consensus Rating of "Moderate Buy" from Analystsmarketbeat.com - February 16 at 1:27 AMSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, CBAY, WISH, AMAMstockhouse.com - February 12 at 3:24 PM47,433 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Acquired by Bank of New York Mellon Corpmarketbeat.com - February 12 at 4:17 AMAMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMbusinesswire.com - February 10 at 11:23 AMTD Asset Management Inc Grows Stock Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)marketbeat.com - January 22 at 5:13 AMAmbrx Biopharma Inc. (NYSE:AMAM) Receives Average Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - January 22 at 2:15 AMSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AXNX, AMAM, HARPstockhouse.com - January 20 at 12:57 PMRobert W. Baird Reiterates "Neutral" Rating for Ambrx Biopharma (NYSE:AMAM)marketbeat.com - January 16 at 3:33 PMJMP Securities Downgrades Ambrx Biopharma (AMAM)msn.com - January 11 at 3:27 PMAmbrx Biopharma (NYSE:AMAM) Rating Reiterated by JMP Securitiesmarketbeat.com - January 10 at 8:33 AMAmbrx Biopharma just downgraded at JMP Securities, here's whyrealmoney.thestreet.com - January 10 at 1:45 AMAmbrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&Jfinance.yahoo.com - January 9 at 3:44 PMAmbrx Biopharma (NYSE:AMAM) Stock Rating Reaffirmed by B. Rileymarketbeat.com - January 9 at 10:22 AMJ&J to buy cancer therapy developer Ambrx for $2 blnnasdaq.com - January 8 at 11:11 PMAMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholderstmcnet.com - January 8 at 11:11 PMJohnson & Johnson: Biotech a shot in the arm for future growth? (AMAM)marketbeat.com - January 8 at 7:43 PMCrude Oil Falls Sharply; Ambrx Biopharma Shares Spike Highermarkets.businessinsider.com - January 8 at 1:09 PMWhy Is Ambrx Biopharma (AMAM) Stock Up 100% Today?investorplace.com - January 8 at 1:06 PMJohnson & Johnson to buy Ambrx Biopharma for $2 blnreuters.com - January 8 at 8:09 AMAmbrx Announces Sale to Johnson & Johnsonfinance.yahoo.com - January 8 at 8:09 AMAmbrx Biopharma Inc. (NYSE:AMAM) Given Consensus Rating of "Moderate Buy" by Analystsmarketbeat.com - December 28 at 2:24 AMCantor Fitzgerald Reaffirms "Overweight" Rating for Ambrx Biopharma (NYSE:AMAM)marketbeat.com - December 21 at 7:36 AMAmbrix to Join NASDAQ Biotech Indexmsn.com - December 14 at 3:05 PMAmbrx to be Added to the NASDAQ Biotechnology Index (NBI)finance.yahoo.com - December 14 at 10:05 AMCommodore Capital LP Has $52.26 Million Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)marketbeat.com - December 10 at 11:01 AMOptimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy Ratingmarkets.businessinsider.com - November 29 at 9:31 PMAmbrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancerfinance.yahoo.com - November 28 at 12:51 PMAnalysts Offer Insights on Healthcare Companies: Twist Bioscience (TWST) and Ambrx Biopharma (AMAM)markets.businessinsider.com - November 18 at 2:07 AMAnalysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Viridian Therapeutics (VRDN)markets.businessinsider.com - November 14 at 6:17 PMGoldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)markets.businessinsider.com - November 14 at 8:16 AMAmbrx Biopharma (AMAM) Price Target Increased by 8.17% to 25.79msn.com - November 1 at 11:17 PMCormorant Asset Management, LP Acquires New Stake in Ambrx Biopharma Incfinance.yahoo.com - October 26 at 10:33 AMRBC Capital Maintains Ambrx Biopharma (AMAM) Outperform Recommendationmsn.com - October 24 at 3:04 PMAmbrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Dataseekingalpha.com - October 24 at 11:23 AMAmbrx Biopharma: Potential With Recently Released Prostate Cancer Dataseekingalpha.com - October 23 at 6:50 PMAnalyst Ratings for Ambrx Biopharmamarkets.businessinsider.com - October 23 at 6:12 PMAmbrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatmentsfinance.yahoo.com - October 23 at 8:11 AMCancer Focused Ambrx Biopharma Stock Trading Lower Today - Here's Whybenzinga.com - October 16 at 7:04 PMAmbrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congressfinance.yahoo.com - October 16 at 9:04 AMWe're Hopeful That Ambrx Biopharma (NASDAQ:AMAM) Will Use Its Cash Wiselyfinance.yahoo.com - October 13 at 2:12 PMAmbrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023finance.yahoo.com - September 26 at 9:56 AMJMP Securities Initiates Coverage on Ambrx Biopharma (NYSE:AMAM)marketbeat.com - September 25 at 7:22 AM Get Ambrx Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide AMAM Media Mentions By Week AMAM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMAM News Sentiment▼0.000.58▲Average Medical News Sentiment AMAM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMAM Articles This Week▼01▲AMAM Articles Average Week Get Ambrx Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INBX News Today FUSN News Today BEAM News Today ADMA News Today NMRA News Today DNA News Today RXRX News Today TARS News Today FDMT News Today VIR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AMAM) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon’s New Device is About to Shock the WorldInvestorPlaceConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
